Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Bcl-xL inhibitor

DRUG CLASS:

Bcl-xL inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	trametinib + dabrafenib + ABT 263 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + ABT 263 Sensitive : C2	trametinib + dabrafenib + ABT 263 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + ABT 263 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	A-1331852 Sensitive: C3 – Early Trials A-1331852 Sensitive : C3	A-1331852 Sensitive: C3 – Early Trials A-1331852 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	ABT 263 Sensitive: C3 – Early Trials ABT 263 Sensitive : C3	ABT 263 Sensitive: C3 – Early Trials ABT 263 Sensitive : C3
BCL2L1 overexpression	Non Small Cell Lung Cancer	BCL2L1 overexpression	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3	osimertinib + APG-1252 Sensitive: C3 – Early Trials osimertinib + APG-1252 Sensitive : C3
STRN-ALK rearrangement	Mesothelioma	STRN-ALK rearrangement	Mesothelioma	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D	ABT 263 Sensitive: D – Preclinical ABT 263 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	trametinib + ABT 263 Sensitive: D – Preclinical trametinib + ABT 263 Sensitive : D	trametinib + ABT 263 Sensitive: D – Preclinical trametinib + ABT 263 Sensitive : D
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D